Neo-adjuvant chemo(radio)therapy in gastric cancer: Current status and future perspectives

Table 2 Peri-operative chemotherapy in resectable gastric cancer

Ref.	Phase	Selection criteria	Study arms	No. of patients	R0 resection (%)	Pathologic CR (%)	Median survival(mo)
Ajani et al[15]	II	M0 Resectable + EGJ	EFP × 2 + surgery + EFP × 3	25	72	0	15
Leichman et al[16]	II	M0 resectable	PFL × 2 + surgery (IP FUDR + IP cisplatin × 2)	8	88	8	> 17
Kang et al[17]	III RCT	M0 Loc. advanced	EFP × 3 + surgery + EFP × 3-6 vs surgery + EFP × 3-6	107 (53 + 54)	79 vs 61	8	43 vs 30
Ajani et al[18]	II	M0 resectable	EAP × 3 + surgery + EAP × 2	48	90	0	16
Rougier et al[19]	II	M0 Loc. advanced + EGJ	FP × 6 + surgery	30	78	0	16
Kelsen et al[11]	II	M0 Loc. advanced	FAMTX × 3 + surgery + IP FP + F	56	77	NS	15
Crookes et al[20]	II	M0 resectable + EGJ	PFL × 2 + surgery (IP FUDR +IP cisplatin × 2)	59	71	9	52
Songun et al[21]	II RCT	T2-T4; M0	FAMTX × 3 + surgery vs surgery alone	56 (27 + 29)	75 vs 75	NS	18 vs 30
Schuhmacher et al[22]	II	III-IV; M0 + EGJ	EAP + surgery	42	86	0	19
D’Ugo et al[23]	II	T3-4 any N; T ≤ 2 N+; M0	EEP × 3 or ECF × 3 + surgery + EEP × 3 or ECF × 3	34	82	3	> 28
Cunningham et al[6] (MAGIC trial)	III RCT	Resectable GC (II-IV); M0 + adenocarcinomas EGJ	ECF × 3 + surgery + ECF × 3 s vs surgery alone	503 (250 + 253)	74 vs 68	NS	18 vs 30
Ychou et al[24] (ACCORD trial)	III RCT	Resectable GC + adenocarcinomas EGJ	FP × 2-3 + surgery + FP × 3-4 vs surgery alone	224 (113 + 111)	84 vs 73	NS	NS
Schuhmacher et al[25] (EORTC trial)	III RCT	Loc. advanced GC T3-T4N × M0	PFL × 2 vs surgery alone	144 (72 + 72)	81.9 vs 66.7	NS	> 36
Kinoshita et al[26]	II	Schirrous resectable	S-1 × 2 + surgery	55	80.8	0	NS
Biffi et al[27]	III RCT	T3-4 any N or any T N1-3 M0 + EGJ	TCF × 4 + surgery vs surgery alone	69 (34 + 35)	85	11.7	NS
Yoshikawa et al[30],	II RCT	T2–3/N+ or T4aN0 + EGJ	SC × 2 + surgery vs SC × 4 + surgery vs PC × 2 + surgery vs PC × 4 + surgery	83 (21 + 20 + 21 + 21)	NS	10 10	NS

EL: Exploratory laparotomies; R0: Curative (R0) resections; CR: Complete response; EFP: Etoposide, fluorouracil, and cisplatin; GC: Gastric cancer; IP: Intraperitoneal; FUDR: 5-fluoro-2’-deoxyuridine; RCT: Randomized controlled trial; EAP: Etoposide, doxorubicin, cisplatin; FP: Fluorouracil, cisplatin; F: Fluorouracil; NS: Not stated; EEP: Etoposide, epirubicin, cisplatin; TCF: Docetaxel, cisplatin, fluorouracil; SC: S1, cisplatin; PC: S, cisplatin.